From: admin Date: Mon, 15 Jun 2020 08:46:19 +0000 (+0000) Subject: updated PO files X-Git-Url: https://source.charles.plessy.org/?a=commitdiff_plain;h=759852540db57e6303fb366afe79a22f94b90ee6;p=setup%2F.git updated PO files --- diff --git a/open-source-biologist.en.po b/open-source-biologist.en.po index 1cf95c10..38eefe8e 100644 --- a/open-source-biologist.en.po +++ b/open-source-biologist.en.po @@ -7,7 +7,7 @@ msgid "" msgstr "" "Project-Id-Version: PACKAGE VERSION\n" -"POT-Creation-Date: 2020-06-15 07:55+0000\n" +"POT-Creation-Date: 2020-06-15 08:46+0000\n" "PO-Revision-Date: YEAR-MO-DA HO:MI+ZONE\n" "Last-Translator: FULL NAME \n" "Language-Team: LANGUAGE \n" @@ -58,25 +58,28 @@ msgid "" "On April 2013, I started a new development cycle as the leader of the " "Genomics Miniaturization Technology Unit at RIKEN Center for Life Sciences, " "Division of Genomics Technology, to expand this work on single cells " -"following a **population transcriptomics** approach (Plessy et al., 2013) " -"focused on sampling the largest possible number of cells. In our ongoing " -"developments, we have reached **single-cell and single molecule resolution** " -"through the introduction of transposase fragmentation and unique molecular " -"identifiers (Poulain et al., 2017). The protocol exists in two versions, one " -"for FACS-isolated cells, and one for the Fluidigm C1 platform (Kouno et al., " -"2019)." +"following a **population transcriptomics** approach ([Plessy and coll., 2013]" +"(https://pubmed.gov/23281054)) focused on sampling the largest possible " +"number of cells. In our ongoing developments, we have reached **single-cell " +"and single molecule resolution** through the introduction of transposase " +"fragmentation and unique molecular identifiers ([Poulain and coll., 2017]" +"(https://pubmed.gov/28349422)). The protocol exists in two versions, one for " +"FACS-isolated cells, and one for the Fluidigm C1 platform ([Kouno and coll., " +"2019](https://pubmed.gov/30664627))." msgstr "" #. type: Plain text msgid "" "I have complemented my work on CAGE with the development of a gene-centred " -"technique for detecting promoters, termed Deep-RACE (Olivarius et al., 2009, " -"Plessy et al., 2012), which we used to validate our discovery of the " -"pervasive expression of retrotransposons detected by CAGE (Faulkner et al., " -"2009). To study transcription start activity at nucleotide resolution in " -"zebrafish transfected with chimeric transgenes containing a copy of an " -"endogenous promoter, I combined Deep-RACE, CAGE and paired-end sequencing in " -"a technology that we called “Single-Locus CAGE” (Haberle et al., 2014). With " +"technique for detecting promoters, termed Deep-RACE ([Olivarius and coll., " +"2009](https://pubmed.gov/19317658), [Plessy and coll., 2012](http://dx.doi." +"org/10.1002/9783527644582.ch4)), which we used to validate our discovery of " +"the pervasive expression of retrotransposons detected by CAGE ([Faulkner and " +"coll., 2009](https://pubmed.gov/19377475)). To study transcription start " +"activity at nucleotide resolution in zebrafish transfected with chimeric " +"transgenes containing a copy of an endogenous promoter, I combined Deep-" +"RACE, CAGE and paired-end sequencing in a technology that we called “Single-" +"Locus CAGE” ([Haberle and coll., 2014](https://pubmed.gov/24531765)). With " "my contributions related to CAGE development and analysis, I have been a " "**member of the FANTOM consortium** since FANTOM3." msgstr "" @@ -85,7 +88,7 @@ msgstr "" msgid "" "Together with my colleagues at RIKEN and collaborators in the field of " "neuroscience, I have applied nanoCAGE to the study of single neuron cell " -"types, for instance the **olfactory neurons** (Plessy et al., 2012), or in " +"types, for instance the **olfactory neurons** ([Plessy et al., 2012), or in " "dopaminergic cells, where we could demonstrate the expression of haemoglobin " "in the midbrain (Biagioli et al., 2009). We are also exploring the sub-" "cellular localisation of RNA in **Purkinje neurons** (Kratz et al., 2014), "